ArticleScientific reports2026
Predictors and outcomes of hepatic decompensation following transarterial locoregional therapy in hepatocellular carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) are recognized locoregional therapies (LRTs) for patients with unresectable hepatocellular carcinoma (uHCC). We assessed the predictors of hepatic decompensation (HD) and its impact on overall survival (OS) in patients with uHCC undergoing TACE and TARE.We analyzed patients treated with TARE (n=135) or TACE (n=177) at four tertiary centers. HD was defined as ascites, variceal bleeding or portosystemic encephalopathy at baseline or its occurrence ≤6 months post LRT. Median OS and objective response (per mRECIST) were assessed.The cohort was predominantly male (73.9%), with a mean age of 67.1 ± 10.5 years; most had intermediate-stage (BCLC B, 54.5%), followed by early-stage (BCLC 0/A, 34.0%) and locally advanced-stage disease (BCLC C, 11.5%). HD was present at baseline in 36 patients (11.5%) and occurred after LRT in 48 patients (15.4%). The post-LRT HD group showed lower complete response rates (10.9%) than those without HD (31.4%; P = 0.002). The mOS was longer in patients without HD (41.0 months) than in those with HD at presentation (15.0 months [HR 2.35; 95% CI: 1.37-4.01) or after LRT (14.0 months [HR, 2.66; 95% CI: 1.68-4.26]). Multivariable analyses revealed hepatitis C etiology (OR 0.28, 95% CI: 0.11-0.66, P = 0.006), ALBI score (OR 2.12, 95% CI: 1.38-3.32, P = 0.001) and intervention with TARE (OR 2.20, 95% CI:1. 11-4.44, P = 0.026) as independent predictors of HD post-LRT.Post-LRT HD is common and strongly associated with reduced survival in patients with uHCC. Baseline hepatic reserve and intervention with TARE are crucial factors in predicting post-LRT HD. These findings underscore that treatment-related hepatic injury can outweigh its benefits when hepatic reserve is marginal.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.